Press Releases

You Narrowed By: Business/Product Release

Showing 36-70 of 174


2012

September

September 12

According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives

September 6

Abbott to Collaborate with Astellas in CMV Vaccine Trial
 

August

August 30

Abbott's HUMIRA® (Adalimumab) Approved in Europe for Expanded Treatment of Crohn’s Disease (CD)

August 28

Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels

August 20

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 7

Abbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment of Iliac Artery Disease
 

July

July 30

Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Non-radiographic Axial Spondyloarthritis (nr-axSpA)

July 13

Abbott Focuses on the Importance of Information Management and Automation at the American Association for Clinical Chemistry Lab Expo

July 11

Abbott Introduces OneLab, a Novel Integrated Web-Based Software Platform to Manage the Vast Amounts of Information Flowing Through the Lab

July 10

Abbott Announces New Test for the Management of Patients with Diabetes

July 3

Abbott Receives FDA Approval for Healon EndoCoat Protective Gel for Cataract Surgery
 

June

June 26

Abbott Introduces New Limited Ingredient Nutrition Bar – Perfectly Simple™ by ZonePerfect®

June 25

Abbott Receives Positive Opinion for HUMIRA® in Non-radiographic Axial Spondyloarthritis from EMA's CHMP

June 18

Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease

June 12

Abbott Expands CFChef Program in 2012 for People Affected by Cystic Fibrosis

June 6

Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis

June 6

Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis

June 6

Abbott Announces 10-Year Data Evaluating HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis

June 5

Abbott Introduces Ensure Clear™ to Help Adults Fill Dietary Gap

June 5

Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis
 

May

May 29

Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (Europe)

May 29

Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (U.S.)

May 16

Abbott Launches PediaSure SideKicks® Clear for Picky Eaters

May 15

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 7

Abbott Reaches Settlement Agreement on Depakote

May 3

Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India

May 3

Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury
 

April

April 25

New Products from Abbott’s EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals

April 23

Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States

April 20

Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery

April 19

Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C

April 19

Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C

April 17

Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer

April 17

Abbott’s Investigational Treatment for Advanced Parkinson’s Disease Demonstrates Positive Results in Phase 3 Clinical Trial

April 11

Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)